Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer.

MLA

Kim, Hyeon Hwa, et al. “Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer.” Cancers, vol. 16, no. 3, Feb. 2024, p. 528. EBSCOhost, https://doi.org/10.3390/cancers16030528.

APA

Kim, H. H., Lee, J. C., Oh, I.-J., Kim, E. Y., Yoon, S. H., Lee, S. Y., Lee, M. K., Lee, J. E., Park, C. K., Lee, K. Y., Lee, S. Y., Kim, S. J., Lim, J. H., & Choi, C. (2024). Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer. Cancers, 16(3), 528. https://doi.org/10.3390/cancers16030528

Chicago

Kim, Hyeon Hwa, Jae Cheol Lee, In-Jae Oh, Eun Young Kim, Seong Hoon Yoon, Shin Yup Lee, Min Ki Lee, et al. 2024. “Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer.” Cancers 16 (3): 528. doi:10.3390/cancers16030528.